sprite-preloader
Freitag, 19.12.2014 Börsentäglich über 12.000 News von 497 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen
23.04.2013 | 08:34
(56 Leser)
Schrift ändern:
(0 Bewertungen)

GlobeNewswire (Europe)·Mehr Nachrichten von GlobeNewswire (Europe)

SYGNIS Pharma / SYGNIS granted US patent for QUALIPHI®, the Next Generation DNA amplification tool . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

New patent opens SYGNIS and QUALIPHI® in a leading position in a €70 million global market.

  • QUALIPHI® is a DNA polymerase which has demonstrated the potential to improve complete DNA amplification from minimal concentrations
  • Polymerase proteins are essential in the research and analysis or modification of DNA
  • QUALIPHI® reduces reaction time to 2 hours
  • Currently, the global DNA amplification market is estimated at €70 million, with the US the largest market.

Madrid/Heidelberg, 23 April 2013 - The biotech company SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) has been granted a patent by the USPTO (US patent and Trademark office) for its flagship product, QUALIPHI® the polymerase for complete DNA amplification. Polymerase proteins are the main tool for amplifying long DNA fragments and whole genomes, and are a basic need for research involving the analysis and modification of DNA.  

QUALIPHI® is an upgraded version of the Phi 29 DNA polymerase used in isothermal amplification which provides enhanced properties compared to similar polymerase proteins on the market. Being less time-consuming and having highly superior performance characteristics, the method developed by SYGNIS enables DNA amplification from concentrations as low as those found in a single cell. This is extremely useful in cancer research, and many other applications.

 "Certainly, the need for amplification of nucleic acids from minimal concentrations as present in single cell applications will be a critical issue in the coming era of personalised medicine and NGS. We expect QUALIPHI® to become an essential tool for the DNA amplification needed in these markets", said SYGNIS' CEO, Pilar de la Huerta.

With the significant growth in the field of DNA amplifications used in sequencing and personalised medicine, the market of whole genome amplification with polymerase proteins is expected to grow at over 20% per annum over the next few years. Current estimates indicate that the size of the global isothermal DNA market alone is approximately €70 million, with the US as the leading market for QUALIPHI®.

In 2012, SYGNIS granted an exclusive global licence to QIAGEN, including sublicensing rights, for the commercialization of QUALIPHI® in the DNA amplification market. QIAGEN is a global leader in sample and assay technologies in research and molecular diagnostics.

About SYGNIS Pharma AG: www.sygnis.de (http://www.sygnis.de/)

After the merger in 2012 between X-Pol Biotech, specialising in DNA amplification and sequencing, and SYGNIS Pharma AG, listed in the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS' new mission is to develop and distribute technologies and products from X-Pol, which has a commercial product in the DNA amplification segment, QUALIPHI®, and is currently developing other products in the field of Next Generation Sequencing.

For further information:
Pilar de la Huerta
CEO/CFO of SYGNIS Pharma AG
,+34 902 02 69 31 / 609 47 29 34 / 654 41 01 11

# # # Disclaimer:
Some statements included in this press release, relating neither to proven financial results nor to other historical data, should be viewed as forward-looking, i.e. not definitive. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature, they are subject to known and unknown risks, as well as to aspects beyond human control, and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. # # #

Press release (PDF) (http://hugin.info/150277/R/1695126/557691.pdf)



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: SYGNIS Pharma via Thomson Reuters ONE

HUG#1695126

--- End of Message ---

SYGNIS Pharma
Im Neuenheimer Feld 515 Heidelberg Germany



© 2013 GlobeNewswire (Europe)